CIBC Asset Management Inc Increases Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

CIBC Asset Management Inc boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 35,529 shares of the medical equipment provider’s stock after buying an additional 1,556 shares during the period. CIBC Asset Management Inc’s holdings in Hologic were worth $2,561,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HOLX. FMR LLC boosted its position in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after buying an additional 2,174,093 shares during the period. Nordea Investment Management AB lifted its stake in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares during the last quarter. Swedbank AB boosted its holdings in Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after acquiring an additional 306,562 shares during the period. JPMorgan Chase & Co. grew its position in Hologic by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after acquiring an additional 238,222 shares during the last quarter. Finally, Barclays PLC increased its stake in Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after purchasing an additional 231,578 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent analyst reports. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Raymond James reissued an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Finally, Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Ten analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Stock Up 0.2 %

NASDAQ:HOLX opened at $64.47 on Friday. The company’s 50-day simple moving average is $69.91 and its 200-day simple moving average is $76.61. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a fifty-two week low of $62.69 and a fifty-two week high of $84.67. The stock has a market capitalization of $14.47 billion, a P/E ratio of 20.34, a P/E/G ratio of 2.13 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.88% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.